

(19) **DANMARK**

(10) **DK/EP 2356221 T3**



Patent- og
Varemærkestyrelsen

(12) Oversættelse af
europæisk patentskrift

-
- (51) Int.Cl.: **C 12 N 5/074 (2010.01)** **C 12 N 15/85 (2006.01)**
- (45) Oversættelsen bekendtgjort den: **2019-02-18**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2018-11-21**
- (86) Europæisk ansøgning nr.: **09744285.9**
- (86) Europæisk indleveringsdag: **2009-10-23**
- (87) Den europæiske ansøgnings publiceringsdag: **2011-08-17**
- (86) International ansøgning nr.: **US2009061935**
- (87) Internationalt publikationsnr.: **WO2010048567**
- (30) Prioritet: **2008-10-24 US 108362 P**
- (84) Designerede stater: **AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR**
- (73) Patenthaver: **Wisconsin Alumni Research Foundation, P.O. Box 7365, Madison, WI 53707-7365, USA**
- (72) Opfinder: **THOMSON, James, 1807 Regent Street, Madison, WI 53726, USA**
YU, Junying, 1265 Meadow Sweet Dr., Madison, WI 53719, USA
- (74) Fuldmægtig i Danmark: **Zacco Denmark A/S, Arne Jacobsens Allé 15, 2300 København S, Danmark**
- (54) Benævnelse: **Pluripotente stamceller opnået ved ikke-viral omprogrammering**
- (56) Fremdragne publikationer:
EP-A1- 2 072 618
WO-A1-2009/133971
WO-A1-2009/149233
WO-A1-2010/012077
WO-A2-2008/118820
YU JUNYING ET AL: "Induced pluripotent stem cell lines derived from human somatic cells" SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 318, no. 5858, 21 December 2007 (2007-12-21), pages 1917-1920, XP009105055 ISSN: 1095-9203
OKITA KEISUKE ET AL: "Generation of Mouse Induced Pluripotent Stem Cells Without Viral Vectors" SCIENCE (WASHINGTON D C), vol. 322, no. 5903, 9 October 2008 (2008-10-09), pages 949-953, XP002571322 ISSN: 0036-8075
YU JUNYING ET AL: "Human induced pluripotent stem cells free of vector and transgene sequences." SCIENCE (NEW YORK, N.Y.) 8 MAY 2009, vol. 324, no. 5928, 8 May 2009 (2009-05-08), pages 797-801, XP002571323 ISSN: 1095-9203
CONESE M ET AL: "Gene therapy progress and prospects: Episomally maintained self-replicating systems" GENE THERAPY, vol. 11, no. 24, December 2004 (2004-12), pages 1735-1741, XP002571324 ISSN: 0969-7128
CAREY B W ET AL: "Reprogramming of murine and human somatic cells using a single polycistronic vector" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 20090106

Fortsættes ...

US, vol. 106, no. 1, 6 January 2009 (2009-01-06), pages 157-162, XP002571325

D'IPPOLITO G ET AL: "Marrow-isolated adult multilineage inducible (MIAMI) cells, a unique population of postnatal young and old human cells with extensive expansion and differentiation potential", JOURNAL OF CELL SCIENCE, CAMBRIDGE UNIVERSITY PRESS, LONDON, GB, vol. 117, no. part 14, 15 June 2004 (2004-06-15), pages 2971-2981, XP002339338, ISSN: 0021-9533, DOI: 10.1242/JCS.01103

VERFAILLIE CATHERINE M: "Multipotent adult progenitor cells: an update", NOVARTIS FOUNDATION SYMPOSIUM, WILEY, CHICHESTER, GB, vol. 265, 1 January 2005 (2005-01-01), page 55, XP009100345, ISSN: 1528-2511, DOI: 10.1002/0470091452.CH5

J. Yu ET AL: "Pluripotent stem cell lines", GENES AND DEVELOPMENT., vol. 22, no. 15, 1 August 2008 (2008-08-01), pages 1987-1997, XP055372545, US ISSN: 0890-9369, DOI: 10.1101/gad.1689808

DESCRIPTION

BACKGROUND

[0001] Embryonic stem (ES) cells hold great promise in science and medicine due to their pluripotent nature, i.e. the ability to replicate indefinitely and differentiate into cells of all three germ layers (Thomson et al., Science 282:1145-1147 (1998)). The application of human ES cells in therapy and regenerative medicine is complicated by the possibility of rejection by the recipient's immune system. Human pluripotent cells that are substantially genetically identical to a particular recipient are, thus, highly desirable. Also, genetic identity may be important for the use of ES cells in designing patient-specific treatment strategies.

[0002] First attempts to generate pluripotent cells from a post-natal primate individual employed somatic nuclear transfer (see, e.g., Byrne, JA et al., Nature 450:497-502 (2007)) and cell fusion (see, e.g., Yu, J et al., Stem Cells 24:168-176 (2006)). However, clinical use of somatic nuclear transfer is impractical due to its low efficiency, while cell fusion results in near tetraploid cells. In 2007, two groups of scientists reprogrammed somatic cells from a post-natal primate individual into pluripotent stem cells (Yu et al., Science 318:1917-1920 (2007) and Takahashi et al., Cell 131:861-872 (2007)). Both groups delivered into, and expressed in, human somatic cells cDNA of four transcription factors using a viral vector system for expressing potency-determining transgenes. The transcription factors of Takahashi et al. were *OCT4*, *SOX2*, *c-Myc*, and *KLF4*, while Yu et al. employed *OCT4*, *SOX2*, *NANOG*, and *LIN28*. The expression of these sets of transcription factors induced human somatic cells to acquire ES cell-specific characteristics, including morphology, proliferation, and gene- and surface marker expression. Somatic cells reprogrammed in this manner are referred to as induced pluripotent (iPS) cells. The existence of iPS cells circumvents the need for blastocysts and reduces concerns associated with immune rejection.

[0003] Shortly thereafter, Lowry et al. generated patient-specific iPS cell lines through ectopic expression of *OCT4*, *SOX2*, *c-Myc*, and *KLF4* (Lowry et al., PNAS 105:2883-2888 (2008)) transgenes. More recently, iPS cells have been generated from a number of different human and murine somatic cell types, such as epithelial, fibroblast, liver, stomach, neural, and pancreatic cells. Further, iPS cells have been successfully differentiated into cells of various lineages (e.g., Dimos et al., Science 321:1218-1221 (2008)).

[0004] Current methods for generating iPS cells employ retroviral vectors such as those derived from lentivirus. These vectors stably integrate into, and permanently change, a target cell's DNA at virtually any chromosomal locus. This untargeted interaction between reprogramming vector and genome is associated with a risk of aberrant cellular gene expression as well as neoplastic growth caused by viral gene reactivation (Okita et al. Nature 448:313-317 (2007)).

[0005] Moreover, continued presence and expression of the transgenes can interfere with the recipient cell's physiology. Further, ectopic expression of transcription factors used to reprogram somatic cells, such as *c-Myc*, can induce programmed cell death (apoptosis) (Askew et al., *Oncogene* 6:1915-1922 (1991), Evan et al., *Cell* 69:119-128 (1992)). Furthermore, continued expression of factors such as *OCT4* can interfere with subsequent differentiation of iPS cells.

[0006] It is desirable to reprogram somatic cells to a state of higher potency without altering the cells' genetic makeup beyond the reprogramming-associated alterations. Recently, Stadtfeld *et al.* generated murine iPS cells using a nonintegrating adenovirus that transiently expressed *OCT4*, *SOX2*, *KLF4*, and *c-Myc* (Stadtfeld et al., *Scienceexpress*, Sep. 25, 2008). To date, primate iPS cells generated without using retroviral vectors have not been reported.

BRIEF SUMMARY

[0007] The present invention is broadly summarized as relating to reprogramming of differentiated primate somatic cells to produce primate pluripotent cells.

[0008] The present invention provides a method of reprogramming primate somatic cells, the method comprising the steps of: exposing the primate somatic cells to at least one non-viral episomal vector encoding a plurality of potency-determining factors and introducing SV40 T antigen into the primate somatic cells under conditions sufficient to reprogram the cells, wherein the primate somatic cells are obtained from a fetal or post-natal individual; and culturing the exposed cells to obtain pluripotent reprogrammed cells substantially free of any non-viral episomal vector component associated with exposing the potency-determining factors to the somatic cells.

[0009] Also disclosed herein is a method for producing a primate pluripotent cell includes the step of delivering into a primate somatic cell a set of transgenes sufficient to reprogram the somatic cell to a pluripotent state, the transgenes being carried on at least one episomal vector that does not encode an infectious virus, and recovering pluripotent cells. References herein to a "non-viral" vector or construct indicate that the vector or construct cannot encode an infectious virus.

[0010] Also disclosed herein is an enriched population of replenishable reprogrammed pluripotent cells of a primate, including a human primate, wherein, in contrast to existing iPS cells, the at least one vector, including any element thereof having a viral source or derivation is substantially absent from the pluripotent cells. As used herein, this means that the reprogrammed cells contain fewer than one copy of the episomal vector per cell, and preferably no residual episomal vector in the cells. Because asymmetric partitioning during cell division dilutes the vector, one can readily obtain reprogrammed cells from which the vector has been lost. As noted elsewhere herein, on very rare occasions a reprogramming vector can integrate into the genome of the cell, but cells having an integrated vector can be avoided by

screening for absence of the vector.

[0011] Further, in contrast to existing ES cells, the primate pluripotent cells produced using the invention are substantially genetically identical to somatic cells from a fetal or post-natal individual. Fetal cells can be obtained from, e.g., amniotic fluid. The cells of the enriched population are not readily distinguished from existing primate ES and iPS cells morphologically (*i.e.*, round shape, large nucleoli and scant cytoplasm) or by growth properties (*i.e.*, doubling time; ES cells have a doubling time of about seventeen to eighteen hours). Like iPS cells and ES cells, the reprogrammed cells also express pluripotent cell-specific markers (*e.g.*, *OCT-4*, *SSEA-3*, *SSEA-4*, *TRA-1-60*, *TRA-1-81*, but not *SSEA-1*). Unlike ES cells, the reprogrammed cells are not immediately derived from embryos. As used herein, "not immediately derived from embryos" means that the starting cell type for producing the pluripotent cells is a non-pluripotent cell, such as a multipotent cell or terminally differentiated cell, such as somatic cells obtained from a fetal or post-natal individual. Like iPS cells, the pluripotent cells produced in the method can transiently express one or more copies of selected potency-determining factors during their derivation.

[0012] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although suitable materials and methods for the practice or testing of the present invention are described below, other materials and methods similar or equivalent to those described herein, which are well known in the art, can be used.

[0013] Other objectives, advantages and features of the present invention will become apparent from the following specification taken in conjunction with the accompanying drawings.

BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS

[0014]

FIG. 1A-B illustrate the effect on reprogramming efficiency of different nucleotide sequences that link transgenes on the vector(s) delivered during the reprogramming methods.

FIG. 2A-C illustrate the effect on reprogramming efficiency of *c-Myc*, *KLF-4*, and SV40 large T antigen gene expression in human newborn foreskin fibroblasts.

FIG. 3A-C illustrate a suitable construct for carrying transgenes into somatic cells in accord with the method, temporal expression of an episomal vector-mediated transgene, and the effect of vector quantity on cell survival after nucleofection.

FIG. 4A-D illustrate reprogramming of human newborn foreskin fibroblasts with episomal vector-mediated transgene expression.

FIG. 5A-B illustrate related constructs harboring an expression cassette useful in the

reprogramming methods of the invention.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

[0015] The present invention broadly relates to novel methods for reprogramming differentiated primate somatic cells obtained from a fetal or post-natal individual into reprogrammed primate cells that are substantially free of the vectors used in their production by introducing SV40 T antigen and introducing potency-determining factors on a non-viral episomal vector that is present during reprogramming, but is substantially absent from the reprogrammed cells. As used herein, "reprogramming" refers to a genetic process whereby differentiated somatic cells are converted into de-differentiated cells having a higher potency than the cells from which they were derived.

[0016] Advantageously, the higher potency cells produced in the method are euploid pluripotent cells. As used herein, "pluripotent cells" refer to a population of cells that express pluripotent cell-specific markers, have a cell morphology characteristic of undifferentiated cells (*i.e.*, compact colony, high nucleus to cytoplasm ratio and prominent nucleolus) and can differentiate into all three germ layers (*e.g.*, endoderm, mesoderm and ectoderm). When introduced into an immunocompromised animal, such as a SCID mouse, the pluripotent cells form teratomas that typically contain cells or tissues characteristic of all three germ layers. One of ordinary skill in the art can assess these characteristics by using techniques commonly used in the art. See, *e.g.*, Thomson *et al.*, *supra*. Pluripotent cells are capable of both proliferation in cell culture and differentiation towards a variety of lineage-restricted cell populations that exhibit multipotent properties. Pluripotent cells have a higher potency than somatic multipotent cells, which by comparison are more differentiated, but which are not terminally differentiated. The pluripotent products of primate somatic cell reprogramming methods are referred to herein as "reprogrammed primate pluripotent cells" or as induced pluripotent (iPS) cells. Such cells are suitable for use in research and therapeutic applications currently envisioned for human ES cells or existing iPS cells.

[0017] Differentiated somatic cells, including cells from a fetal, newborn, juvenile or adult primate, including human, individual, are suitable starting cells in the methods. Suitable somatic cells include, but are not limited to, bone marrow cells, epithelial cells, endothelial cells, fibroblast cells, hematopoietic cells, keratinocytes, hepatic cells, intestinal cells, mesenchymal cells, myeloid precursor cells and spleen cells. Another suitable somatic cell is a CD29⁺ CD44⁺ CD166⁺ CD105⁺ CD73⁺ and CD31⁻ mesenchymal cell that attaches to a substrate. Alternatively, the somatic cells can be cells that can themselves proliferate and differentiate into other types of cells, including blood stem cells, muscle/bone stem cells, brain stem cells and liver stem cells. Suitable somatic cells are receptive, or can be made receptive using methods generally known in the scientific literature, to uptake of potency-determining factors including genetic material encoding the factors. Uptake-enhancing methods can vary depending on the

cell type and expression system. Exemplary conditions used to prepare receptive somatic cells having suitable transduction efficiency are well-known by those of ordinary skill in the art. The starting somatic cells can have a doubling time of about twenty-four hours.

[0018] The vectors described herein can be constructed and engineered using methods generally known in the scientific literature to increase their safety for use in therapy, to include selection and enrichment markers, if desired, and to optimize expression of nucleotide sequences contained thereon. The vectors should include structural components that permit the vector to self-replicate in the somatic starting cells. For example, the known Epstein Barr oriP/Nuclear Antigen-1 (EBNA-1) combination (see, e.g., Lindner, S.E. and B. Sugden, The plasmid replicon of Epstein-Barr virus: mechanistic insights into efficient, licensed, extrachromosomal replication in human cells, *Plasmid* 58:1 (2007),) is sufficient to support vector self-replication and other combinations known to function in mammalian, particularly primate, cells can also be employed. Standard techniques for the construction of expression vectors suitable for use in the present invention are well-known to one of ordinary skill in the art and can be found in publications such as Sambrook J, et al., "Molecular cloning: a laboratory manual," (3rd ed. Cold Spring harbor Press, Cold Spring Harbor, N.Y. 2001).

[0019] In the methods, genetic material encoding a set of potency-determining factors is delivered into the somatic cells via one or more reprogramming vectors. Suitable potency-determining factors can include, but are not limited to OCT-4, SOX2, LIN28, NANOG, c-Myc, KLF4, and combinations thereof. Each potency-determining factor can be introduced into the somatic cells as a polynucleotide transgene that encodes the potency-determining factor operably linked to a heterologous promoter that can drive expression of the polynucleotide in the somatic cell. Although SV40 T Antigen is not a potency-determining factor *per se*, it advantageously introduced into somatic cells as it provides the cells with a condition sufficient to promote cell survival during reprogramming while the potency-determining factors are expressed. Other conditions sufficient for expression of the factors include cell culture conditions described in the examples.

[0020] Suitable reprogramming vectors are episomal vectors, such as plasmids, that do not encode all or part of a viral genome sufficient to give rise to an infectious or replication-competent virus, although the vectors can contain structural elements obtained from one or more virus. One or a plurality of reprogramming vectors can be introduced into a single somatic cell. One or more transgenes can be provided on a single reprogramming vector. One strong, constitutive transcriptional promoter can provide transcriptional control for a plurality of transgenes, which can be provided as an expression cassette. Separate expression cassettes on a vector can be under the transcriptional control of separate strong, constitutive promoters, which can be copies of the same promoter or can be distinct promoters. Various heterologous promoters are known in the art and can be used depending on factors such as the desired expression level of the potency-determining factor. It can be advantageous, as exemplified below, to control transcription of separate expression cassettes using distinct promoters having distinct strengths in the target somatic cells. Another consideration in selection of the transcriptional promoter(s) is the rate at which the promoter(s) is silenced in the target somatic

cells. The skilled artisan will appreciate that it can be advantageous to reduce expression of one or more transgenes or transgene expression cassettes after the product of the gene(s) has completed or substantially completed its role in the reprogramming method. Exemplary promoters are the human EF1 α elongation factor promoter, CMV cytomegalovirus immediate early promoter and CAG chicken albumin promoter, and corresponding homologous promoters from other species. In human somatic cells, both EF1 α and CMV are strong promoters, but the CMV promoter is silenced more efficiently than the EF1 α promoter such that expression of transgenes under control of the former is turned off sooner than that of transgenes under control of the latter.

[0021] The potency-determining factors can be expressed in the somatic cells in a relative ratio that can be varied to modulate reprogramming efficiency. For example, somatic cell reprogramming efficiency is fourfold higher when *OCT-4* and *SOX2* are encoded in a single transcript on a single vector in a 1:1 ratio than when the two factors are provided on separate vectors, such that the uptake ratio of the factors into single cells is uncontrolled. Preferably, where a plurality of transgenes is encoded on a single transcript, an internal ribosome entry site is provided upstream of transgene(s) distal from the transcriptional promoter. Although the relative ratio of factors can vary depending upon the factors delivered, one of ordinary skill in possession of this disclosure can determine an optimal ratio of factors.

[0022] The skilled artisan will appreciate that the advantageous efficiency of introducing all factors via a single vector rather than via a plurality of vectors, but that as total vector size increases, it becomes increasingly difficult to introduce the vector. The skilled artisan will also appreciate that position of a factor on a vector can affect its temporal expression, and the resulting reprogramming efficiency. As such, Applicants employed various combinations of factors on combinations of vectors. Several such combinations are here shown to support reprogramming.

[0023] After introduction of the reprogramming vector(s) and while the somatic cells are being reprogrammed, the vectors can persist in target cells while the introduced transgenes are transcribed and translated. Transgene expression can be advantageously downregulated or turned off in cells that have been reprogrammed to a pluripotent state. The reprogramming vector(s) can remain extra-chromosomal. At extremely low efficiency, the vector(s) can integrate into the cells' genome. The reprogramming vector(s) replicate coordinately with the recipient cell's genome and, as such, are reasonably stable for about two weeks, longer than episomal vectors that cannot replicate their DNA. Nevertheless, because the vectors are not partitioned evenly at cell division, in the absence of selective pressure, cells lose the episomal vector(s) so one can readily recover vector-free pluripotent cells in the method. For example, it usually takes two-to-three weeks for oriP/EBNA-1-based episomal plasmids to be stably maintained in somatic cells. During the initial two-to-three weeks, cells quickly lose episomal plasmids. Once the cells are stabilized, the cells continue to lose episomal vector at ~5% per generation.

[0024] Pluripotent cells produced in the method can be cultured in any medium that supports

pluripotent cell growth, including but not limited to a defined medium, such as TeSR™ (StemCell Technologies, Inc.; Vancouver, Canada), mTeSR™ (StemCell Technologies, Inc.) and StemLine® serum-free medium (Sigma; St. Louis, Mo.), or a conditioned medium such as mouse embryonic fibroblast (MEF)-conditioned medium. As used herein, a "defined medium" refers to a biochemically defined formulation comprised solely of biochemically-defined constituents which can include constituents of known chemical composition or constituents derived from known sources. As used herein, "conditioned medium" refers to a growth medium that is further supplemented with soluble factors from cells cultured in the medium. Alternatively, cells can be maintained on MEFs in culture medium.

[0025] The invention will be more fully understood upon consideration of the following non-limiting Examples.

EXAMPLES

Example 1

Design and construction of expression cassettes

[0026] Suitable expression cassette structures were created using conventional methods by direct polymerase chain reaction (PCR) amplification of open reading frames (ORFs) from some or all of the transgenes, using the first and last 20-22 bases of the coding region as primers, and from the Internal Ribosome Entry Sites listed in Table 1. The sources of SV40 T Antigen and human telomerase reverse transcriptase, plasmids pBABE-puro SV40 LT and pBABE-hygro-hTERT, are commercially available from Addgene, Inc, Cambridge, MA, as plasmids 13970 and 1773, respectively. The sources of IRES1 and IRES2, plasmids pIRESpuro3 and pIRES2EGFP, are commercially available from Clontech Laboratories, Inc., Mountain View, CA. Foot-and-mouth disease virus segment 2, was chemically synthesized. In-frame expression cassettes are described using the codes set forth below in Table 1. For example, "E-O2S" refers to an expression cassette having an EF1α promoter upstream of the OCT4 and SOX2 coding regions, with IRES2 therebetween. Likewise, "C-M2K" refers to an expression cassette having a CMV promoter upstream of the c-Myc and Klf4 coding regions, with IRES2 therebetween. In several constructs, none of which was used in subsequent reprogramming, a variant O2S expression cassette ("O2S(2)") was employed that differed from O2S in that it contained a TK promoter - Hyg - TK polyA cassette (compare FIG. 5A and 5B). Cassettes having the indicated structures were selected for subsequent use in reprogramming methods by empirical determination of expression levels of various factors. The promoter designated as EF2 (SEQ ID NO:12) was a slight variant from the known EF1α promoter (SEQ ID NO:11) that did not differ from EF1α in activity and which was not used in subsequent episomal vector reprogramming trials, *infra*. The F2A is a peptide linker that facilitates co-

translation of distinct coding regions expressed from a single transcript. F2A was tested but was not used in subsequent reprogramming trials using episomal vectors. IRES1 was tested but was not used in subsequent reprogramming trials using episomal vectors.

[0027] The relative effects of various promoters, IRES sequences, and transgene arrangements on the expression of the upstream and downstream ORFs were evaluated by separately cloning various transgene expression cassettes into pSin4, a modified lentivirus-based vector, to test their ability to reprogram human somatic cells after transfection, as previously described (Yu *et al.*, *supra*). 293FT cells were transfected with lentiviral plasmid vectors expressing *OCT4* and *SOX2* linked by IRES1 or IRES2 using SuperFect (Qiagen, Valencia, CA), as depicted below. Cells were collected two days post-transfection. FIG. 1A shows a Western blot analysis of OCT-4 and SOX2 in 293FT cells. Lane 1, *pSIN4-EF2-OCT4-IRES1-SOX2*; lane 2, *pSIN4-EF2-OCT4-IRES2-SOX2*; lane 3, *pSIN4-EF2-OCT4-F2A-SOX2*; lane 4, *pSIN4-EF2-OCT4-IRES1-PURO*; lane 5, *pSIN4-EF2-SOX2-IRES1-PURO*; lane 6, no plasmid (control). Mouse anti-human OCT4 monoclonal antibody (1:500, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, sc-5279) and goat anti-human SOX2 polyclonal antibody (1:500, R&D Systems, Minneapolis, MN AF2018) were used to detect the relative expression of OCT4 and SOX2 respectively.

[0028] FIG. 1B shows reprogramming using linked potency-determining factors in 0.2×10^6 mesenchymal cells derived (Yu *et al.*, *supra*) from *OCT4* knock-in human ES cells (US Patent Application No. 2006/0128018 and Zwaka and Thomson, Nature Biotechnology 21:319-321 (2003)). This line was maintained under neomycin selection (geneticin: 100 µg/ml, Invitrogen Corp.). Human iPS cell colonies were counted on day 16 post-transduction. The gene combinations were *pSIN4-EF2-OCT4-IRES1-SOX2* (O1S); *pSIN4-EF2-OCT4-IRES2-SOX2* (O2S); *pSIN4-EF2-OCT4-F2A-SOX2* (OF2AS); *pSIN4-EF2-NANOG-IRES1-LIN28* (N1L); *pSIN4-EF2-NANOG-IRES2-LIN28* (N2L); *pSIN4-EF2-OCT4-IRES1-PURO* (O); *pSIN4-EF2-SOX2-IRES1-PURO* (S); *pSIN4-EF2-NANOG-IRES1-PURO* (N); *pSIN4-EF2-LIN28-IRES1-PURO* (L). The abbreviation used for each lentiviral plasmid vector is shown in parentheses after the vector name.

Example 2

Reprogramming human newborn foreskin fibroblasts using lentiviral constructs

[0029] Preliminary reprogramming experiments were conducted by introducing lentiviral vectors into human neonatal foreskin fibroblasts. FIG. 2A shows that *NANOG* has a profound positive effect on reprogramming efficiency when *OCT4*, *SOX2*, *LIN28*, and *c-MYC* are also introduced, and that in combination with *OCT4*, *SOX2*, and *LIN28*, *NANOG* can support reprogramming, even in the absence of *c-MYC* or *KLF4*. Lentiviral constructs used were *pSIN4-EF2-OCT4-IRES2-SOX2* (O2S); *pSIN4-EF2-NANOG-IRES2-LIN28* (N2L); *pSIN4-EF2-*

LIN28-IRES1-PURO (L); *pSIN4-CMV-c-Myc-IRES1-PURO* (M); *pSIN4-EF2-KLF4-IRES1-PURO* (K). Twenty-one days after transduction, alkaline phosphatase-positive human iPS cell colonies were counted. The number of iPS cell colonies were derived from an input of 2.5×10^4 human newborn foreskin fibroblasts (passage 9). The light gray bars represent the total number of reprogrammed colonies formed having typical human ES cell morphology; dark gray bars indicate the number of large colonies with minimal differentiation.

[0030] FIG. 2B evidences reprogramming using linked potency-determining factors. Lentiviral constructs used were *pSIN4-EF2-c-Myc-IRES2-KLF4* (EF2-M2K); *pSIN4-CMV-c-Myc-IRES2-KLF4* (CMV-M2K); *pSIN4-EF2-KLF4-IRES2-c-Myc* (EF2-K2M); *pSIN4-CMV-KLF4-IRES2-c-Myc* (CMV-K2M); *pSIN4-CMV-c-Myc-IRES2-LIN28* (M2L); *pSIN4-EF2-NANOG-IRES2-KLF4* (N2K). Fourteen days after transduction, alkaline phosphatase-positive human iPS cell colonies were counted. The number of iPS cell colonies were derived from an input of approximately 7.0×10^4 foreskin fibroblasts (passage 12). The asterisk indicates that most of the alkaline phosphatase-positive colonies appeared morphologically loose.

[0031] FIG. 2C shows the effect of SV40 large T antigen gene expression on reprogramming efficiency. SV40 large T antigen prevents c-Myc-induced in murine fibroblasts (Hermeking et al., PNAS 91:10412-10416 (1994)) and enhances reprogramming efficiency (Hanna et al., Cell 133:250-264 (2008); Mali et al., Stem Cells doi: 10.1634/stemcells.2008-0346 (2008)). Abbreviations of gene combinations are the same as in FIG. 2B, with the addition of SV40 large T antigen (T). c-Myc also promotes cell proliferation. Twelve days after transduction, alkaline phosphatase-positive human iPS cell colonies were counted. The number of iPS cell colonies were derived from an input of approximately $\sim 3.5 \times 10^4$ foreskin fibroblasts (passage 17). Fig. 2C demonstrates that if present at levels achieved during lentiviral-based reprogramming, T antigen inhibits final stages of iPS cell derivation. In contrast, see *infra*, wherein T antigen does not have this effect when present for the temporal expression time and/or level achieved during reprogramming using episomal vectors. In addition, T antigen prevents c-Myc-induced apoptosis but does not adversely affect c-Myc-induced cell proliferation.

Example 3

Reprogramming of human newborn foreskin fibroblasts using non-viral episomal constructs

[0032] Human newborn foreskin fibroblasts (Cat# CRL-2097™, ATCC) were maintained in foreskin fibroblast culture medium (DMEM (Cat# 11965, Invitrogen) supplemented with 10% heat-inactivated fetal bovine serum (FBS, HyClone Laboratories, Logan, UT), 2 mM Glutamax, 0.1 mM non-essential amino acids, and 0.1 mM β -mercaptoethanol).

[0033] Various combinations of potency-determining factors provided as transgene expression cassettes constructed as in Example 1 and as detailed below in Table 3 were introduced into somatic cells using an episomal construct pCEP4-EGFP (as shown in Fig. 3A) resulting in reprogramming with varying efficiency. pCEP4-EGFP was created from commercially available mammalian episomal expression vector pCEP4 (Invitrogen Corp., Carlsbad, CA) by inserting the EGFP coding region between the pCEP4 BamHI and NheI sites. The episomal vectors of Table 2 were created by inserting the designated expression cassettes into pCEP4-EGFP or into a related backbone lacking P_{CMV} (designated pEP4). See Fig. 3A and Table 2 footnotes for cloning sites into which expression cassettes were inserted.

[0034] Vectors were introduced into the fibroblasts via a single nucleofection event, using Human Dermal Fibroblasts Nucleofector Kit (Normal Human Dermal Fibroblasts, Amaxa, Inc. Cat. No. VPD-1001), in accord with the manufacturer's instructions. After nucleofection, the transfected fibroblasts (~ 0.8 to 1.0 x 10⁶ cells each) were immediately plated onto three 10 cm dishes seeded with irradiated mouse embryonic fibroblasts (MEF). Foreskin fibroblast culture medium was replaced every other day. After four days, the foreskin fibroblast culture medium was replaced with human ES cell culture medium (DMEM/F12 culture medium supplemented with 20% KnockOut serum replacer, 0.1 mM non-essential amino acids (all from Invitrogen Corp.), 1 mM Glutamax, 0.1 mM β-mercaptoethanol and 100 ng/ml zebrafish basic fibroblast growth factor (zbFGF) as previously described (Amit et al., *Developmental Biology* 227:271-278 (2006); Ludwig et al., *Nature Methods* 3:637-646 (2006)). When the seeded MEF could no longer sustain the reprogramming culture, about 8 to 10 days after plating, human ES cell culture medium conditioned with irradiated MEF was used instead. When appropriate (about 2-3 weeks after transfection), the cultures were stained for alkaline phosphatase as an indication of human iPS colony development.

[0035] To determine suitable parameters for introducing transgene constructs, temporal expression was initially evaluated by measuring EGFP level over time after introduction of EGFP from pEGFP-N2 (control) and pCEP4-EGFP episomal vector into 293FT cells was evaluated (Fig. 3B).

[0036] The effect of the amount of transgene construct introduced on human newborn foreskin fibroblast cell survival was also evaluated in preliminary experiments. FIG. 3C shows the effect of amount of pCEP4-EGFP episomal vector used on nucleofection efficiency and survival of human newborn foreskin fibroblasts, estimated from cell confluence on the day after nucleofection. Approximately 1 x 10⁶ nucleofected foreskin fibroblasts were plated into each well of a 6-well plate. Gray lines represent non-transfected control fibroblasts; black lines represent transfected fibroblasts.

[0037] Fig. 4A depicts schematic transgene expression constructs from Table 3 containing various expression cassettes that when introduced in certain combinations into human newborn foreskin fibroblasts result in reprogramming of the fibroblasts to pluripotent cells. Three combinations of introduced episomal reprogramming vectors have yielded

reprogrammed pluripotent cells: (1) pEP4-E-O2S-E-T2K, pEP4-E-O2S-E-N2K and pCEP4-C-M2L; (2) pEP4-E-O2S-C-K2M-E-N2L and pEP4-E-O2S-E-T2K; and (3) pEP4-E-O2S-EN2L, pEP4-E-O2S-E-T2K and pEP4-E-O2S-E-M2K. Table 3 indicates the amount of each vector used in each successful combination. One vector in each successful reprogramming combination encoded T antigen under control of the EF1 α promoter.

[0038] FIG. 4B shows a bright-field microscopy image of a typical colony with morphological changes observed 18 days after episomal vector transfection. FIG. 4C shows a bright-field microscopy image of an alkaline phosphatase-positive colony 18 days after episomal vector transfection.

[0039] Twenty-five to thirty days after transfection, the reprogramming cultures were passaged once to fresh 10 cm MEF dishes (1:3 ratio), due to the presence of many non-iPS cell colonies with morphologies similar to human iPS cell colonies. Colonies were then picked for further analysis. FIG. 4D shows a bright-field microscopy image of a human iPS cell colony 6 days after the first passage of day 28 post-transfection reprogramming culture. The scale bar represents 0.1 mm. Reprogrammed cells were maintained for subsequent analysis in feeder-free culture on Matrigel (BD Biosciences, Bedford, MA) with conditioned medium as previously described (Xu et al., Nat. Biotechnol. 19:971 (2001)).

[0040] Advantageously, the reprogramming efficiency of greater than 1% of the newborn foreskin fibroblast cells reprogrammed was achieved, at significantly lower reprogramming time than was achieved using four gene combinations.

TABLE 1 -- Reprogramming genes and translation elements

Gene Symbol	Abbr.	Source	SEQ ID NO	Accession # or sequence
<i>OCT4</i>	O	hESC	1	NM_002701
<i>SOX2</i>	S	hESC	2	NM_003106
<i>NANOG</i>	N	hESC	3	NM_024865
<i>LN28</i>	L	hESC	4	NM_024674
<i>c-Myc</i>	M	hESC	5	NM_002467
<i>KLF4</i>	K	hESC	6	NM_004235
<i>SV40 T</i>	T	pBABE-puro SV40 LT p	7	EF579667
<i>TERT</i>	TERT	pBABE-hygro-hTERT	8	NM_198253
IRES 1	1	pIRESpuro3	--	
IRES2	2	pIRES2EGFP	--	
F2A	F2A	(synthesized)	9	
CMV	C		10	
EF1 α	E		11	

Gene Symbol	Abbr.	Source	SEQ ID NO	Accession # or sequence
EF2α	-		12	

TABLE 2: Episomal constructs

#	Name	Size (bp)
1	pCEP4-EGFP	10984
2 ^b	pEP4-E-O2S(2)	13523
3 ^b	pEP4-E-M2K	14293
4 ^a	pCEP4-M2K	13643
5 ^b	pEP4-E-K2M	14268
6 ^a	pCEP4-K2M	13636
7 ^b	pEP4-E-N2K	13819
8 ^b	pEP4-E-T2K	15071
9 ^a	pCEP4-M2L	12852
10 ^b	pEP4-E-N2L	13020
11 ^b	pEP4-E-T2L	14284
12 ^c	pEP4-E-O2S-C-M2K	16038
13 ^c	pEP4-E-O2S-E-M2K	16680
14 ^c	pEP4-E-O2S-C-K2M	16010
15 ^c	pEP4-E-O2S-E-K2M	16652
16 ^c	pEP4-E-O2S-E-N2K	16206
17 ^c	pEP4-E-O2S-E-T2K	17458
18 ^c	pEP4-E-O2S-E-N2L	15415
19 ^c	pEP4-E-O2S-E-T2L	16679
20 ^c	pEP4-O2S-C-M2L	15247
21 ^c	pEP4-E-O2S-E-K2T	17474
22 ^c	pEP4-E-O2S-C-M2L-E-N2K	19956
23 ^c	pEP4-E-O2S-C-M2K-E-N2L	19956
24 ^c	pEP4-E-O2S-C-K2M-E-N2L	19949
25 ^c	pEP4-E-O2S-C-M2L-E-T2K	21220
26 ^c	pEP4-E-O2S-C-M2K-E-T2L	21220
27 ^c	pEP4-E-O2S-C-K2M-E-T2L	21213

#	Name	Size (bp)
28 ^c	pEP4-E-O2S-C-M2L-E-K2T	21224

^a All linked gene cassettes were cloned into the pCEP4-EGFP between BamHI and NheI restriction sites.

^b All linked gene cassettes plus the EF1 α promoter were cloned into the pCEP4-EGFP between BamHI and SpeI (19) restriction sites.

^c All expression cassettes were cloned into the pCEP4-EGFP between BamHI and NruI restriction sites.

TABLE 3: Combinations of episomal constructs tested for reprogramming activity

Equivalent of pCEP4-EGF(μ g)	Test #	Plasmids	μ g	Morph. Changes	AP+ colony /plate
EXPERIMENT 1					
6.3	1	pEP4-E-O2S-C-M2K	9.2	+/-	0
6.3	2	pEP4-E-O2S-K2Neo	9.3	+/-	0
6.3		pCEP4-M2L	7.4		
6.3	3	pEP4-E-O2S-E-N2K	9.3	+/-	0
6.3		pCEP4-M2L	7.4		
6.3	4	pEP4-E-O2S-E-T2K	10	+++	0
6.3		pCEP4-M2L	7.4		
6.3	5	pEP4-E-O2S-E-TERT2K	10.8	+/-	0
6.3		pCEP4-M2L	7.4		
6.3	6	pEP4-E-O2S-C-M2L	8.7	+/-	0
6.3		pEP4-E-N2K	7.9		
6.3	7	pEP4-E-O2S-C-M2L	8.7	+	0
6.3		pEP4-E-T2K	8.6		
6.3	8	pEP4-E-O2S-C-M2L	8.7	+/-	0
6.3		pEP4-E-TERT2K	9.4		
EXPERIMENT 2					
3.3	1	pEP4-E-O2S-C-M2K	5.0	+/-	0
3.3	2	pEP4-E-O2S-E-M2K	5.0	+/-	0
3.3	3	pEP4-E-O2S-C-K2M	5.0	+/-	0
3.3	4	pEP4-E-O2S-E-K2M	5.0	+/-	0
2.5	5	pEP4-E-O2S(2)	3.0	+/-	0
2.5		pCEP4-M2K	3.0		
2.5	6	pEP4-E-O2S(2)	3.0	+/-	0
2.3		pEP4-E-M2K	3.0		
2.5	7	pEP4-E-O2S(2)	3.0	+/-	0
2.5		pCEP4-K2M	3.0		
2.5	8	pEP4-E-O2S(2)	3.0	+/-	0
2.3		pEP4-E-K2M	3.0		
1.7	9N	pEP4-E-O2S(2)	2.0	+/-	0
1.5		pEP4-E-N2K	2.0		
1.7		pCEP4-M2L	2.0	+/-	0
1.7	10N	pEP4-E-O2S(2)	2.0	+/-	0
1.7		pEP4-E-N2L	2.0		
1.7		pCEP4-M2K	2.0		
1.7	11N	pEP4-E-O2S(2)	2.0	+/-	0
1.7		pEP4-E-N2L	2.0		
1.5		pEP4-E-M2K	2.0		

1.7	12N	pEP4-E-O2S(2)	2.0	+/-	0
1.7		pEP4-E-N2L	2.0		
1.7		pCEP4-K2M	2.0		
1.7	13N	pEP4-E-O2S(2)	2.0	+/-	0
1.7		pEP4-E-N2L	2.0		
1.5		pEP4-E-K2M	2.0		
2.3	14N	pEP4-E-O2S-E-N2K	3.5	+/-	0
2.1		pCEP4-M2L	2.5		
2.5	15N	pEP4-E-O2S-E-N2L	3.5	+/-	0
2.1		pCEP4-M2K	2.5		
2.5	16N	pEP4-E-O2S-E-N2L	3.5	+/-	0
1.9		pEP4-E-M2K	2.5		
2.5	17N	pEP4-E-O2S-E-N2L	3.5	+/-	0
2.1		pCEP4-K2M	2.5		
2.5	18N	pEP4-E-O2S-E-N2L	3.5	+/-	0
1.9		pEP4-E-K2M	2.5		

EXPERIMENT 3

1.7	9T	pEP4-E-O2S(2)	2.0	++	0
1.4		pEP4-E-T2K	2.0		
1.7		pCEP4-M2L	2.0		
1.7	10T	pEP4-E-O2S(2)	2.0	+	0
1.5		pEP4-E-T2L	2.0		
1.7		pCEP4-M2K	2.0		
1.7	11T	pEP4-E-O2S(2)	2.0	+	0
1.5		pEP4-E-T2L	2.0		
1.5		pEP4-E-M2K	2.0		
1.7	12T	pEP4-E-O2S(2)	2.0	+/-	0
1.5		pEP4-E-T2L	2.0		
1.7		pCEP4-K2M	2.0		
1.7	13T	pEP4-E-O2S(2)	2.0	+/-	0
1.5		pEP4-E-T2L	2.0		
1.5		pEP4-E-K2M	2.0		
2.2	14T	pEP4-E-O2SET2K	3.5	+++	0
2.1		pCEP4-M2L	2.5		
2.3	15T	pEP4-E-O2S-E-T2L	3.5	+	0
2.1		pCEP4-M2K	2.5		
2.3	16T	pEP4-E-O2S-E-T2L	3.5	+	0
1.9		pEP4-E-M2K	2.5		
2.3	17T	pEP4-E-O2S-E-T2L	3.5	+/-	0
2.1		pCEP4-K2M	2.5		
2.3	18T	pEP4-E-O2S-E-T2L	3.5	+/-	0
1.9		pEP4-E-K2M	2.5		
1.9	19	pEP4-E-O2S-E-T2K	3.0	+++	1
2.0		pEP4-E-O2S-E-N2K	3.0		

1.7		pCEP4-M2L	2.0		
EXPERIMENT 4					
6	1	pEP4-E-O2S-C-M2K-E-N2L	10.9	+/-	0
4	2	pEP4-E-O2S-C-M2K-E-N2L	7.3	+++	0
2		pEP4-E-O2S-E-T2K	3.2		
		pEP4-E-O2S-C-K2M-E-N2L			

0	3	N2L	10.9	+/-	0
4	4	pEP4-E-O2S-C-K2M-E-N2L	7.3	++	2
2		pEP4-E-O2S-E-T2K	3.2		
3	5	pEP4-E-O2S-E-N2L	4.2	+/-	0
3		pEP4-E-O2S-E-M2K	4.6		
3	6	pEP4-E-O2S-E-N2L	4.2	++	1
2		pEP4-E-O2S-E-T2K	3.2		
3		pEP4-E-O2S-E-M2K	4.6		
3	7	pEP4-E-O2S-E-N2L	4.2	+/-	0
3		pEP4-E-O2S-C-M2K	4.4		
3	8	pEP4-E-O2S-E-N2L	4.2	+	0
2		pEP4-E-O2S-E-T2K	3.2		
3		pEP4-E-O2S-C-M2K	4.4		
3	9	pEP4-E-O2S-E-N2L	4.2	+/-	0
3		pEP4-E-O2S-E-K2M	4.5		
3	10	pEP4-E-O2S-E-N2L	4.2	+/-	0
2		pEP4-E-O2S-E-T2K	3.2		
3		pEP4-E-O2S-E-K2M	4.5		
3	11	pEP4-E-O2S-E-N2L	4.2	+/-	0
3		pEP4-E-O2S-C-K2M	4.4		
3	12	pEP4-E-O2S-E-N2L	4.2	+	0
2		pEP4-E-O2S-E-T2K	3.2		
3		pEP4-E-O2S-C-K2M	4.4		
2	13	pEP4-E-O2S-C-M2L-E-T2K	3.9	+	0
4		pEP4-E-O2S-E-N2K	5.9		
6	14	pEP4-E-O2S-C-M2K-E-T2L	11.6	+	0
3	15	pEP4-E-O2S-C-M2K-E-T2L	5.8	+	0
3		pEP4-E-O2S-E-N2K	4.4		
6	16	pEP4-E-O2S-C-K2M-E-T2L	11.6	+/-	0
3	17	pEP4-E-O2S-C-K2M-E-T2L	5.8	+	0
3		pEP4-E-O2S-E-N2K	4.4		

6	18	pEP4-E-O2S-C-M2L-E-K2T	11.6	+/-	0
3	19	pEP4-E-O2S-C-M2L-E-K2T	5.8	+/-	0
3		pEP4-E-O2S-E-N2K	4.4		
3	20	pEP4-E-O2S-E-K2T	4.8	+/-	0
3		pEP4-E-O2S-E-N2K	4.4		
2		pEP4-E-O2S-C-M2L	2.8		

+/-: No or very few colonies with morphological change were observed (fig. FIG. 4B).

+, ++ and +++: Different number (from less to more) of colonies with morphological change were observed.

SEQUENCE LISTING

[0041]

<110> WARF

<120> NON-VIRAL REPROGRAMMING

<130> 960296.00914

Sequence

<213> OrganismName : Homo sapiens

<400> PreSequenceString :

ccttcgcaag ccctcatttc accaggcccc cggcttgggg cgccttcctt ccccatggcg	60
ggacacctgg cttcggattt cgctttctcg cccctccag gtggtggagg tgatgggcca	120
ggggggcccg agccgggctg ggttgatcct cggacctggc taagcttcca aggcctcct	180
ggagggccag gaatcgggcc gggggttggg ccaggctctg aggtgtgggg gattcccca	240
tgccccccgc cgtatgagtt ctgtgggggg atggcgctact gtgggccccca ggttgagtg	300
gggctagtgc cccaaggcgg cttggagacc tctcagcctg agggcgaaagc aggagtcggg	360
gtggagagca actccgatgg ggcctccccg gagccctgca ccgtcacccc tggtgccgtg	420
aagctggaga aggagaagct ggagcaaac ccggaggagt ccaggacat caaagctctg	480
cagaaagaac tcgagcaatt tgccaagctc ctgaagcaga agaggatcac cctgggatat	540
acacaggccg atgtggggct caccctgggg gttctatttg ggaaggattt cagccaaacg	600
accatctgcc gctttgaggc tctgcagctt agcttcaaga acatgtgtaa gctgcggccc	660
ttgctgcaga agtgggtgga ggaagctgac aacaatgaaa atcttcagga gatatgcaa	720
gcagaaaccc tcgtgcaggc ccgaaagaga aagcgaacca gtatcgagaa ccgagtgaga	780
ggcaacctgg agaatttgtt cctgcagtgc ccgaaaccca cactgcagca gatcagccac	840
atcggccagc agcttgggct cgagaaggat gtggtccgag tgtggttctg taaccggcgc	900
cagaagggca agcgatcaag cagcgactat gcacaacgag aggattttga ggctgctggg	960
tctcctttct cagggggacc agtgtccttt cctctggccc cagggccccca ttttggtacc	1020
ccaggctatg ggagccctca cttcactgca ctgtactcct cggctccctt ccctgagggg	1080
gaagcctttc cccctgtctc cgtcaccact ctgggctctc ccatgcattc aaactgaggt	1140
gcctgccctt ctaggaatgg gggacagggg gaggggagga gctagggaaa gaaaacctgg	1200
agttttgtgc aggggttttg ggattaagtt cttcattcac taaggaggga attggaaca	1260
caaaggggtg gggcagggga gtttggggca actggttgga ggggaaggta agttcaatga	1320
tgctcttgat tttaatccca catcatgtat cacttttttc ttaaataaag aagcctggga	1380
cacagtagat agacacactt aaaaaaaaaa a	1411

<212> Type : DNA

<211> Length : 1411

SequenceName : SEQ ID NO:1

SequenceDescription :

Sequence

<213> OrganismName : Homo sapiens

<400> PresequenceString :

ctattaactt gttcaaaaaa gtatcaggag ttgtcaaggc agagaagaga gtgtttgcaa	60
gggggggggg gttatgttact gctctttttt ggttgggact gggggggggg gggggggggg	120

aayyyyyaaa ylaylllycl gcccclllaa yallayyall yagayaaaya ayayyyayaya	120
gaaagaaagg gagagaagtt tgagccccag gcttaagcct ttccaaaaaa taataataac	180
aatcatcggc ggcggcagga tcggccagag gaggagggaa gcgctttttt tgatcctgat	240
tccagtttgc ctctctcttt ttttccccca aattattctt cgcttgattt tcctcgcgga	300
gccccgcgct cccgacaccc ccgcccgcct cccctctctc tctccccccg cccgcgggct	360
ccccaaagtc ccggccgggc cgagggtcgg cggccgccgg cgggcccggc ccgcgcacag	420
cgcccgcatg tacaacatga tggagacgga gctgaagccg ccgggcccgc agcaaaattc	480
ggggggcggc ggcggcaact ccaccgggc ggcgggccgc ggcaaccaga aaaacagccc	540
ggaccgcgtc aagcggccca tgaatgcctt catggtgtgg tcccgcgggc agcggcgcaa	600
gatggcccag gagaacccca agatgcacaa ctcgagatc agcaagcgcc tgggcgcccga	660
gtggaaactt ttgtcggaga cggagaagcg gccgttcacg gacgaggcta agcggctcgc	720
agcgtgcac atgaaggagc acccggatta taaataccgg ccccggcgga aaaccaagac	780
gctcatgaag aaggataagt acacgtgcc cggcgggctg ctggcccccg gcggcaatag	840
catggcgagc ggggtcgggg tgggcgcccg cctgggcgcg ggcgtgaacc agcgcattga	900
cagttacgcg cacatgaacg gctggagcaa cggcagctac agcatgatgc aggaccagct	960
gggtacccg cagcaccg gctcaatgc gcacggcgca gcgcagatgc agcccatgca	1020
ccgtacgac gtgagcgccc tgcagtacaa ctccatgacc agctcgaga cctacatgaa	1080
cggctcgccc acctacagca tgcctactc gcagcagggc acccctggca tggctcttgg	1140
ctccatgggt tcgggtgtca agtccgaggc cagctccagc cccctgtgg ttacctcttc	1200
ctccactcc agggcgccct gccaggccgg ggacctccg gacatgatca gcatgtatct	1260
ccccggcgcc gaggtgccgg aaccgcccgc cccagcaga ctccacatgt cccagcacta	1320
ccagagcggc ccggtgccgg gcacggccat taacggcaca ctgcccctct cacacatgtg	1380
agggccggac agcgaactgg aggggggaga aattttcaaa gaaaaacgag ggaaatggga	1440
ggggtgcaaa agaggagagt aagaaacagc atggagaaaa cccggtacgc tcaaaaagaa	1500
aaaggaaaaa aaaaaatccc atcacccaca gcaaatgaca gctgcaaaag agaacaccaa	1560
tcccattcac actcacgcaa aaaccgcgat gccgacaaga aaacttttat gagagagatc	1620
ctggacttct ttttggggga ctatttttgt acagagaaaa cctggggagg gtggggaggg	1680
cgggggaatg gaccttgtat agatctggag gaaagaaagc tacgaaaaac tttttaaaag	1740
ttctagtgg acggtaggag ctttgcagga agtttgcaaa agtctttacc aataatattt	1800
agagctagtc tccaagcgac gaaaaaatg ttttaatat ttgcaagcaac ttttgtacag	1860
tatttatcga gataaacatg gcaatcaaaa tgtccattgt ttataagctg agaatttgcc	1920
aatatttttc aaggagaggc ttcttgctga attttgattc tgcagctgaa atttaggaca	1980
gttgcaaacg tgaaaagaag aaaattattc aaatttgga attttaattg tttaaaaatt	2040
gtacaaaagg aaaaaattag aataagtact ggcgaaccat ctctgtggtc ttgtttaaaa	2100
agggcaaaag ttttagactg tactaaattt tataacttac tgttaaaagc aaaaatggcc	2160
atgcagggtg acaccgttgg taatttataa tagcttttgt tcgatcccaa ctttccattt	2220
tgttcagata aaaaaacca tgaaattact gtgtttgaaa tattttctta tggtttgtaa	2280
tatttctgta aatttattgt gatattttaa ggttttcccc cttttatttt ccgtagttgt	2340
attttaaaag attcggctct gtattatttg aatcagctcg ccgagaatcc atgtatatat	2400
ttgaactaat atcatcctta taacaggtag attttcaact taagttttta ctccattatg	2460
cacagtttga gataaataaa tttttgaaat atggacactg aaaaaaaaaa aaaaaaaa	2518

<211> Length : 2518

SequenceName : SEQ ID NO:2

SequenceDescription :

Sequence

<213> OrganismName : Homo sapiens

<400> PreSequenceString :

attataaatc tagagactcc āggattttaa cgttctgctg gactgagctg gttgcctcat	60
gttattatgc aggcaactca ctttatccca atttcttgat acttttcctt ctggagggtcc	120
tattttctcta acatcttcca gaaaagtctt aaagctgcct taaccttttt tccagtccac	180
ctcttaaatt ttttcctcct ettcctctat actaacatga gtgtggatcc agcttgtccc	240
caaagcttgc ctgcttttga agcatccgac tgtaaagaat cttcacctat gcctgtgatt	300
tgtgggcctg aagaaaacta tccatccttg caaatgtctt ctgctgagat gcctcacacg	360
gagactgtct ctctctctcc ttcttccatg gatctgctta ttcaggacag ccctgattct	420
tccaccagtc ccaaaaggcaa acaaccact tctgcagaga agagtgtcgc aaaaaaggaa	480
gacaagggtcc cgggtcaagaa acagaagacc agaactgtgt tctcttccac ccagctgtgt	540
gtactcaatg atagatttca gagacagaaa tacctcagcc tccagcagat gcaagaactc	600
tccaacatcc tgaacctcag ctacaaacag gtgaagacct gggtccagaa ccagagaatg	660
aaatctaaga ggtggcagaa aaacaactgg ccgaagaata gcaatggtgt gacgcagaag	720
gcctcagcac ctacctaccc cagcctttac tcttcctacc accagggatg cctggtgaac	780
ccgactggga accttccaat gtggagcaac cagacctgga acaattcaac ctggagcaac	840
cagacccaga acatccagtc ctggagcaac cactcctgga aactcagac ctggtgcacc	900
caatcctgga acaatcaggc ctggaacagt ccttcttata actgtggaga ggaatctctg	960
cagtcctgca tgcagttcca gccaaattct cctgccagtg acttgaggc tgccttgga	1020
gctgctgggg aaggccttaa tgtaatacag cagaccacta ggtattttag tactccacaa	1080
accatggatt tattcctaaa ctactccatg aacatgcaac ctgaagacgt gtgaagatga	1140
gtgaaactga tattactcaa tttcagtctg gacactggct gaatecttcc tctccctcc	1200
tcccatccct cataggattt ttctgtttg gaaaccacgt gttctggtt ccatgatgcc	1260
catccagtc aatctcatgga ggggtggagta tgggtggagc ctaatcagcg aggtttctt	1320
tttttttttt ttcttattgg atcttctg agaaaaatact tttttttttt ttttttttga	1380
aacggagtct tgcctgtctg cccaggctgg agtgagtg cgcggtcttg gctcactgca	1440
agctccgtct cccgggttca cgccattctc ctgcctcagc ctcccagca gctgggacta	1500
caggcgcccg ccacctcgcc cggctaatat tttgtatttt tagtagagac ggggtttcac	1560
tgtgttagcc aggatggtct cgatctcctg accttgatgat ccacccgcct cggcctccct	1620
aacagctggg atttacaggc gtgagccacc gcgccttgcc tagaaaagac attttaataa	1680
ccttggtgctc cgtctctggc tatagataag tagatctaact actagtttg atactcttag	1740
ggtttagaat ctaacctcaa gaataagaaa tacaagtaca aattggtgat gaagatgat	1800
tcgtattgtt tgggattggg aggctttgct tattttttta aaactattga ggtaaagggt	1860
taagctgtaa cataactaat tgatttctta ccgtttttgg ctctgttttg ctatatcccc	1920
taatttggtg gttgtgctaa tctttgtaga aagaggtctc gtatttgctg catcgtaatg	1980
acatgagtac tgcttttagtt ggtttaagtt caaatgaatg aaacaactat ttttccttta	2040
-----	2000

gttgattttaa cccctgatttc accgagtggt tcaatgagta aatatacagc ttaaacaat 2098

<212> Type : DNA

<211> Length : 2098

SequenceName : SEQ ID NO:3

SequenceDescription :

Sequence

<213> OrganismName : Homo sapiens

<400> PreSequenceString :

gtgcggggga agatgtagca gcttcttctc cgaaccaacc ctttgccttc ggacttctcc	60
ggggccagca gccgcccgc caggggcccg gggccacggg ctcagccgac gaccatgggc	120
tccgtgtcca accagcagtt tgcaggtggc tgcgccaagg cggcagaaga ggcgcccag	180
gaggcgcccg aggacgcggc ccggcgggcg gacgagcctc agctgctgca cggtgcgggc	240
atctgtaagt ggttcaacgt gcgcatgggg ttcggcttcc tgtccatgac cggcgcgcc	300
ggggtcgcgc tcgaccccc agtggtatgtc tttgtgcacc agagtaagct gcacatggaa	360
gggttccgga gcttgaagga gggtagggca gtggagtcca cctttaagaa gtcagccaag	420
ggtctggaat ccatccgtgt caccggacct ggtggagtat tctgtattgg gagtgaagg	480
cggccaaaag gaaagagcat gcagaagcgc agatcaaaag gagacaggtg ctacaactgt	540
ggaggtctag atcatcatgc caaggaatgc aagctgccac ccagcccaa gaagtgccac	600
ttctgccaga gcatcagcca tatggtagcc tcatgtccgc tgaaggccca gcagggccct	660
agtgcacagg gaaagccaac ctactttcga gaggaagaag aagaaatcca cagccctacc	720
ctgctcccgg aggacagaa ttgagccaca atgggtgggg gctattcttt tgctatcagg	780
aagttttgag gagcaggcag agtggagaaa gtgggaatag ggtgcattgg ggctagttag	840
cactgccatg tatctcaggc ttgggttcac accatcacc tttcttcct ctagggtggg	900
ggaaagggtg agtcaaagga actccaacca tgctctgtcc aaatgcaagt gagggttctg	960
ggggcaacca ggagggggga atcacccctac aacctgcata ctttgagtct ccatccccag	1020
aatttccagc ttttgaaagt ggcctggata ggggaagtgt tttcctttta aagaaggata	1080
tataataatt cccatgccag agtgaaatga ttaagtataa gaccagattc atggagccaa	1140
gccactacat tctgtggaag gagatctctc aggagtaagc attgtttttt tttcacatct	1200
tgtatcctca taccactttt tgggataggg tgctggcagc tgtcccaagc aatgggtaat	1260
gatgatggca aaaaggggtg ttgggggaac agctgcagac ctgctgctct atgctcacc	1320
ccgccccatt ctgggccaat gtgattttat ttatttgctc ccttggatac tgcaccttg	1380
gtcccacttt ctccaggatg ccaactgcac tagctgtgtg cgaatgacgt atcttgtgca	1440
ttttaacttt ttttccttaa tataaatatt ctggttttgt atttttgtat attttaact	1500
aaggccctca tttcctgcac tgtgttctca ggtacatgag caatctcagg gatagccagc	1560
agcagctcca ggtctgcgca gcaggaatta cttttgttg tttttgccac cgtggagagc	1620
aactatttgg agtgcacagc ctattgaaat acctcatttt tgccaataag agctggcttt	1680
tctgccatag tgcctcttg aaacccctc tgccttgaaa atgttttatg ggagactagg	1740
ttttaactgg gtggcccat gacttgattg cttctactg gaagattggg aattagtcta	1800
aacaggaaat ggtgtgtacac agaggctagg agaggctggg cccggtgaaa aggccagaga	1860
gcaagccaag attaggtgag ggttgtctaa tcctatggca caggacgtgc tttacatctc	1920
-----	1980

cagatctgtt cttcaccaga ttaggttagg cctaccatgt gccacagggc gtgtgtgtgt	1980
ttgtaaaact agagttgcta aggataagtt taaagaccaa taccctgtga cttaatcctg	2040
tgctgtcgag ggatggatat atgaagtaag gtgagatcct taacctttca aaattttcgg	2100
gttccagggg gacacacaag cgagggtttt gtgggtgcctg gagcctgtgt cctgccctgc	2160
tacagttagtg attaatagtg tcatggtagc taaaggagaa aaaggggggt tcgtttacac	2220
gctgtgagat caccgcaaac ctacctact gtgttgaaac gggacaaatg caatagaacg	2280
cattgggtgg tgtgtgtctg atcctgggtt cttgtctccc ctaaagtctg cccccaagt	2340
tactgtattt gtctgggctt tgtaggactt cactacgttg attgctaggt ggcttagttt	2400
gtgtaaatat aatgtattgg tctttctccg tgttctttgg gggttttgtt tacaaacttc	2460
tttttgtatt gagagaaaaa tagccaaagc atctttgaca gaagggtctg caccaggcaa	2520
aaagatctga aacattagtt tggggggccc tcttcttaaa gtggggatct tgaaccatcc	2580
tttcttttgt attccccctc ccctattacc tattagacca gatcttctgt cctaaaaact	2640
tgtcttctac cctgccctct tttctgttca ccccaaaaag aaaacttaca ccccacaca	2700
catacacatt tcatgcttg agtgtctcca caactcttaa atgatgtatg caaaaatact	2760
gaagctagga aaacctcca tcccttggtc ccaacctcct aagtcaagac cattaccatt	2820
tctttcttct tttttttttt ttttttaaaa tggagtctca ctgtgtcacc caggctggag	2880
tgcagtggca tgatcggtc actgcagcct ctgcctcttg ggttcaagt attctcctgc	2940
ctcagcctcc tgagtagctg ggatttcagg caccgccac actcagctaa tttttgtatt	3000
tttagtagag acgggggttc accatgttgt ccaggctggt ctggaactcc tgacctcagg	3060
tgatctgccc accttggtt cccaaagtgc tgggattaca ggcattgagc accatgctgg	3120
gccaaccatt tcttggtgta ttcattgcaa acacttaaga cactgtctga gccagggcgc	3180
gggtggctcac acctgtaatc ccagcacttt ggaaggctga ggcggggcga tcacaaggtc	3240
acgagttcaa aactatcctg gccaacacag tgaaaccccg tctctactaa aatacaaaaa	3300
aattagccgg gtgtgggtgt gcatgccttt agtcctagct attcaggagg ctgaggcagg	3360
ggaatcgctt gaacccgaga ggcagagggt gcagtgaact gagatcgac cactgcactc	3420
cagcctgggt acagagcaag actctgtctc aaacaaaaca aaacaaaaca aaaacacact	3480
actgtatttt ggatggatca aacctcctta attttaattt ctaatcctaa agtaaagaga	3540
tgcaattggg ggccttccat gtagaaagt gggtcaggag gccaaagaa ggaatatgaa	3600
tgtatatcca agtcactcag gaacttttat gcagggtgcta gaaactttat gtcaaagtgg	3660
ccacaagatt gttaatatag agacgaacga atgtaactcc atgtttactg ctaaaaacca	3720
aagctttgtg taaaatcttg aatttatggg gcggggagggt aggaagcct gtacctgtct	3780
gtttttttcc tgatcctttt ccttcattcc tgaactgcag gagactgagc ccctttgggc	3840
tttggtgacc ccatcactgg ggtgtgttta tttgatggtt gattttgctg tactgggtac	3900
ttcctttccc attttctaata catTTTTTaa cacaagctga ctcttccctt cccttctcct	3960
ttccttggga aaatacaatg aataaataaa gacttattgg tacgcaaact gtca	4014

<212> Type : DNA

<211> Length : 4014

SequenceName : SEQ ID NO:4

SequenceDescription :

sequence

<213> OrganismName : Homo sapiens

<400> PreSequenceString :

acccccgagc tgtgctgctc gcggccgcca ccgcccggcc ccgcccgtcc ctggctcccc	60
tcctgcctcg agaagggcag ggcttctcag aggcttggcg ggaaaaagaa cggagggagg	120
gatcgcgctg agtataaaag ccggttttcg gggctttatc taactcgctg tagtaattcc	180
agcgagaggc agagggagcg agcgggaggc cggctagggg ggaagagccg ggcgagcaga	240
gctgcgctgc gggcgctcctg ggaagggaga tccggagcga atagggggct tcgcctctgg	300
cccagccctc ccgctgatcc cccagccagc ggtccgcaac ccttgccgca tccacgaaac	360
tttgcccata gcagcgggagc ggcactttgc actggaactt acaacacccg agcaaggacg	420
cgactctccc gacgcgggga ggctattctg cccatttggg gacacttccc cgccgctgcc	480
aggaccgct tctctgaaag gctctccttg cagctgctta gacgctggat ttttttcggg	540
tagtggaata ccagcagcct cccgcgacga tgcccctcaa cgttagcttc accaacagga	600
actatgacct cgactacgac tcggtgcagc cgtatttcta ctgcgacgag gaggagaact	660
tctaccagca gcagcagcag agcgagctgc agcccccgcc gccagcagag gatattctga	720
agaaattcga gctgctgccc accccgcccc tgtcccctag ccgcccgtcc gggctctgct	780
cgccctccta cgttgcggtc acacccttct ccttcggggg agacaacgac ggcgggtggcg	840
ggagcttctc cacggccgac cagctggaga tgggtaccga gctgctggga ggagacatgg	900
tgaaccagag tttcatctgc gaccggagc acgagacctt catcaaaaac atcatcatcc	960
aggactgtat gtggagcggc ttctcggccg ccgccaagct cgtctcagag aagctggcct	1020
cctaccaggc tgcgcgcaaa gacagcggca gcccgaaacc cgcccgcggc cacagcgtct	1080
gctccacctc cagcttgtag ctgcaggatc tgagcgcgcg cgcctcagag tgcacgacc	1140
cctcgggtgg ttccccctac cctctcaacg acagcagctc gcccaagtcc tgcgcctcgc	1200
aagactccag cgcccttctt ccgtccctcg attctctgct ctctcgcagc ggtcctccc	1260
cgcagggcag ccccgagccc ctggtgctcc atgaggagac accgcccacc accagcagcg	1320
actctgagga ggaacaagaa gatgaggaa agaatcgatgt tgtttctgtg gaaaagaggc	1380
aggctcctgg caaaaggcca gactctggat cacttctgc tggaggccac agcaaacctc	1440
ctcacagccc actggtctc aagaggtgcc acgtctccac acatcagcac aactacgcag	1500
cgcctccctc cactcggag gactatcctg ctgccaagag ggtcaagttg gacagtgtca	1560
gagtcttag acagatcagc aacaaccgaa aatgcaccag cccaggtcc tcggacaccg	1620
aggagaatgt caagaggcga acacacaacg tcttgagcgc ccagaggagg aacgagctaa	1680
aacggagctt ttttgccctg cgtgaccaga tcccggagtt ggaaaacaat gaaaaggccc	1740
ccaaggtagt tatccttaaa aaagccacag catacatcct gtccgtccaa gcagaggagc	1800
aaaagctcat ttctgaagag gacttggtgc ggaaacgacg agaacagttg aaacacaaac	1860
ttgaacagct acggaactct tgtgcgtaag gaaaagtaag gaaaacgatt ccttctaaca	1920
gaaatgtcct gagcaatcac ctatgaactt gtttcaaagt catgatcaaa tgcaacctca	1980
caaccttggc tgagtcttga gactgaaaga tttagccata atgtaaactg cctcaaattg	2040
gactttgggc ataaaagaac ttttttatgc ttaccatctt ttttttttct ttaacagatt	2100
tgtatttaag aattgttttt aaaaaatttt aagatttaca caatgtttct ctgtaaatat	2160
tgccattaaa tgtaaataac ttaataaaa cgtttatagc agttacacag aatttcaatc	2220
ctagtatata gtacctagta ttataggtac tataaacctt aatttttttt atttaagtac	2280
attttgcttt ttaaagttga ttttttcta ttgttttag aaaaaataaa ataactggca	2340
aatatatcat tgagccaaaa aaaaaaaaaa aaaaaaa	2377

<212> Type : DNA

<211> Length : 2377

SequenceName : SEQ ID No:5

SequenceDescription :

Sequence

<213> OrganismName : Homo sapiens

<400> PreSequenceString :

```

agtttcccgā cāgagagaa cgaacgtgtc tgcgggcgcg cggggagcag aggcggtggc      60
gggcggcggc ggcaccggga gccgccgagt gacctcccc cgccctctg gccccccacc      120
ctcccaccg cccgtggccc gcgccatgg ccgcgcgcg tccacacaac tcaccggagt      180
ccgcgccttg cgcgcggac cagttcgag ctccgcgcca cggcagccag tctcacctgg      240
cggcaccgcc cgcccaccgc cccggccaca gcccctgcgc ccacggcagc actcgaggcg      300
accgcgacag tggtagggga cgtgctgag tggagagag cgcagcccgg ccaccggacc      360
tacttactcg cttgctgat tgtctat tgcgtttaca acttttctaa gaaetttgt      420
atacaaagga actttttaaa aaagacgctt ccaagttata ttaatacaa agaagaagga      480
tctcggccaa ttgggggttt tgggttttgg ctctgtttct tctcttcgtt gactttgggg      540
ttcagggtgc ccagctgctt cgggctgccg aggaccttct gggcccccac attaatgagg      600
cagccacctg gcgagtctga catggctgtc agcgacgcgc tgctcccatc tttctccacg      660
ttcgcgtctg gcccgggcgg aagggagaag aactgcgtc aagcagggtg cccgaataac      720
cgctggcggg aggagctctc ccacatgaag cgacttcccc cagtgttcc cgccgcccc      780
tatgacctgg cggcggcgac cgtggccaca gacctggaga gcggcggagc cgggtgcggct      840
tgccggcgga gcaacctggc gccctacct cggagagaga ccgaggagtt caacgatctc      900

ctggacctgg actttattct ctccāattcg ctgacccatc ctccggagtc agtggccgcc      960
accgtgtcct cgtcagcgtc agcctcctct tcgtcgtcgc cgtcagcag cggccctgcc      1020
agcgcgcccct ccacctgcag cttcacctat ccgatccggg ccgggaacga cccgggcgtg      1080
gcgcggggcg gcacggggcg aggcctcctc tatggcaggg agtccgctcc ccctccgacg      1140
gtcccttca acctggcgga catcaacgac gtgagccct cgggcggctt cgtggccgag      1200
ctcctgcggc cagaattgga cccggtgtac attccgcgc agcagccgca gccgccagg      1260
ggcgggctga tgggcaagt cgtgctgaag gcgtcgtga gcgcccctg cagcagtag      1320
ggcagcccgt cggatcatag cgtcagcaaa ggcagccctg acggcagcca cccggtggtg      1380
gtggcgcctt acaacggcgg gccgcgcgc agtgcccca agatcaagca ggaggcggtc      1440
tcttcgtgca cccacttggg cgtggaccc cctctcagca atggccaccg gccggctgca      1500
cacgacttcc ccctggggcg gcagctcccc agcaggacta ccccgaccct gggctctgag      1560
gaagtgtgta gcagcaggga ctgtaccct gccctgcgc ttctctccgg ctccatccc      1620
caccggggc ccaattacc atccttctg cccgatcaga tgcagccgca agtcccgcg      1680
ctccattacc aagagctcat gccaccggg tcctgcatgc cagaggagcc caagccaaag      1740
aggggaagac gatcgtggcc ccgaaaagg accgccacc acacttgtga ttacgcggg      1800
tgccgcaaaa cctacacaaa gatttcccat ctcaaggcac acctgcgaac ccacacagg      1860
gagaaacctt accactgtga ctgggacggc tgtggatgga aattcgcccg ctcatgaa      1920
ctgaccaggc actaccgtaa acacacgggg caccgcccgt tccagtcca aaaatgcgac      1980

```



```

cgagcatttt ccaggtcggg ccacctcgcc ttacacatga agaggcattt ttaaattccca 2040
gacagtggat atgaccacac ctgccagaag agaattcagt attttttact tttcacactg 2100
tcttcccgat gagggagga gccagccag aaagcactac aatcatggtc aagttcccaa 2160
ctgagtcacg ttgtgagtgg ataatacagga aaaatgagga atccaaaaga caaaaatcaa 2220
agaacagatg ggggtctgtg ctggatcttc tatcattcca attctaaatc cgacttgaat 2280
attcctggac ttacaaaatg ccaagggggg gactggaagt tgtggatata agggatataa 2340
ttatatccgt gagttggggg agggagacc agaattccct tgaattgtgt attgatgcaa 2400
tataagcata aaagatcacc ttgtattctc ttacattctt aaaagccatt attatgatgt 2460
tagaagaaga ggaagaaatt caggtagaga aaacatgttt aaatagccta aatgatggtg 2520
cttggtgagt cttggttcta aaggtagcaa acaaggaagc caaagttttc aaactgctgc 2580
atactttgac aaggaaaatc tatatttgtc ttccgatcaa catttatgac ctaagtcagg 2640
taatatacct gggttacttc tttagcattt ttatgcagac agtctgttat gactgtggtt 2700
ttcagatgtg caataatttg tacaatggtt tattcccaag tatgccttaa gcagaacaaa 2760
tgtgtttttc tatatagttc ctgccttaa taaatatgta atataaattt aagcaaacgt 2820

ctattttgta tatttgtaaa ctacaaagta aaatgaacat tttgtggagt ttgtattttg 2880
catactcaag gtgagaatta agttttaaat aaacctataa tattttatct gaaaaaaaaa 2940
aaaaaaaaa 2949

```

<212> Type : DNA

<211> Length : 2949

SequenceName : SEQ ID NO:6

SequenceDescription :

Sequence

<213> OrganismName : Simian virus 40

<400> PreSequenceString :

```

agtttccgga ccagagagaa cgaacgtgtc tgcgggcgcg cggggagcag aggcggtggc 60
gggcggcggc ggcaccggga gccgccgagt gacctcccc cgccccctcg gccccccacc 120
ctccccaccg cccgtggccc gcgccatgg ccgcgcgcgc tccacacaac tcaccggagt 180
ccgcgccttg cgcgccgac cagttcgcag ctccgcgcca cggcagccag tctcacctgg 240
cggcaccgcc cgccccaccg cccggccaca gccctgcgc ccacggcagc actcgaggcg 300
accgcgacag tgggtggggga cgctgctgag tggaagagag cgcagcccgg ccaccggacc 360
tacttactcg ccttgctgat tgtctatttt tgcgtttaca acttttctaa gaacttttgt 420
atacaaagga actttttaaa aaagacgctt ccaagttata tttaattcaa agaagaagga 480
tctcggccaa tttggggttt tgggttttgg cttcgtttct tctcttcggt gactttgggg 540
ttcaggtgcc ccagctgctt cgggctgccg aggaccttct gggcccccac attaatgagg 600
cagccacctg cgcagtcctga catggctgtc agcgcgcgc tgcctccatc tttctccacg 660
ttcgcgtctg gcccgggcggg aaggagaga acactgcgtc aagcagggtgc cccgaataac 720
cgctggcggg agggagctct ccacatgaag cgacttcccc cagtgcctcc cggccgcccc 780
tatgacctgg cggcgccgac cgtggccaca gacctggaga gcggcggagc cgggtgcggct 840
tgcggcggta gcaacctggc gccctacct cggagagaga ccgaggagtt caacgatctc 900
ctggacctgg actttattct ctccaattcg ctgacctatc ctccggagtc agtggccgcc 960

```

accgtgtcct	cgtcagcgtc	agcctcctct	tcgtcgtcgc	cgtcgagcag	cggccctgcc	1020
agcgcgcccc	ccacctgcag	cttcacctat	ccgatccggg	ccgggaacga	cccgggctg	1080
gcgcccggcg	gcacgggcgg	aggcctctc	tatggcagg	agtccgctcc	ccctccgacg	1140
gctcccttca	acctggcgga	catcaacgac	gtgagccct	cgggcggctt	cgtggccgag	1200
ctcctgcggc	cagaattgga	cccgggtgtac	attccgcgc	agcagccgca	gccgccagg	1260
ggcgggtgta	tgggcaagtt	cgtgctgaag	gcgtcgtga	gcgcccctgg	cagcgagtac	1320
ggcagccgt	cgggtcatcag	cgtcagcaaa	ggcagccctg	acggcagcca	cccgggtggtg	1380
gtggcgcct	acaacggcgg	gccgcgcgc	acgtgcccc	agatcaagca	ggaggcggtc	1440
tcttcgtgca	cccacttggg	cgctggaccc	cctctcagca	atggccaccg	gccggctgca	1500
cacgacttcc	ccctggggcg	gcagctcccc	agcaggacta	ccccgaccct	gggtcttgag	1560
gaagtgtgta	gcagcaggga	ctgtcacct	gccctgccgc	ttcctcccgg	cttccatccc	1620
cacccggggc	ccaattaccc	atccttctg	cccgatcaga	tgcagccgca	agtcccgcg	1680
ctccattacc	aagagctcat	gccaccgggt	tcctgcattg	cagaggagcc	caagccaaag	1740
aggggaagac	gatcgtggcc	ccggaaaagg	accgccacc	acacttgtga	ttacgcgggc	1800
tgcggcaaaa	cctacacaaa	gagttcccat	ctcaaggcac	acctgcgaac	ccacacagg	1860
gagaaacctt	accactgtga	ctgggacggc	tgtggatgga	aattcgcccg	ctcagatgaa	1920
ctgaccaggc	actaccgtaa	acacacgggg	caccgcccgt	tccagtgcc	aaaatgcgac	1980
cgagcatttt	ccaggctcga	ccacctcgcc	ttacacatga	agaggcattt	ttaaatccca	2040
gacagtggat	atgaccaca	ctgccagaag	agaattcagt	attttttact	tttcacactg	2100
tcttcccgat	gagggaaagga	gccagccag	aaagcactac	aatcatggtc	aagtcccaa	2160
ctgagtcatt	ttgtgagtgg	ataatcagga	aaaatgagga	atccaaaaga	caaaaatcaa	2220
agaacagatg	gggtctgtga	ctggatcttc	tatcattcca	attctaaatc	cgacttgaat	2280
attcctggac	ttacaaaatg	ccaaggggg	gactggaagt	tgtggatata	agggatataa	2340
ttatatccgt	gagttggggg	agggagacc	agaattccct	tgaattgtgt	attgatgcaa	2400
tataagcata	aaagatcacc	ttgtattctc	tttaccttct	aaaagccatt	attatgatgt	2460
tagaagaaga	ggaagaaatt	caggtagaga	aaacatgttt	aaatagccca	aatgatgggtg	2520
cttgggtgagt	cttgggttcta	aaggtagcaa	acaaggaagc	caaagttttc	aaactgctgc	2580
atactttgac	aaggaaaatc	tatatttgtc	ttccgatcaa	catttatgac	ctaagtcagg	2640
taatatacct	ggtttacttc	tttagcattt	ttatgcagac	agtctgttat	gcactgtgggt	2700
ttcagatgtg	caataatttg	tacaatgggt	tattcccaag	tatgccttaa	gcagaacaaa	2760
tgtgtttttc	tatatagtgc	cttgccttaa	taaatatgta	atataaattt	aagcaaacgt	2820
ctattttgta	tattttgtaa	ctacaaagta	aaatgaacat	tttgtggagt	ttgtattttg	2880
catactcaag	gtgagaatta	agttttaaat	aaacctataa	tattttatct	gaaaaaaaaa	2940
aaaaaaaaa						2949

<212> Type : DNA

<211> Length : 2949

SequenceName : SEQ ID NO:7

SequenceDescription :

Sequence

<213> OrganismName : Homo sapiens

<400> PreSequenceString :

caggcagcgc tgcgtcctgc tgcgcacgtg ggaagccctg gccccggcca cccccgcgat	60
gccgcgcgct ccccgctgcc gagccgtgcg ctccctgctg cgcagccact accgcgaggt	120
gctgccgctg gccacgttcg tgcggcgccct ggggccccag ggctggcggc tggtgacgcg	180
cggggaccctg gcggctttcc gcgcgctggt ggcccagtg cttggtgtgcg tgccttggga	240
cgcacggccg cccccgcgg cccctectt ccgccaggtg tcctgcctga aggagctggt	300
ggcccagtg ctgcagaggc tgtgcgagcg cggcgcgaag aacgtgctgg ccttcggctt	360
cgcgctgctg gacggggccc gcggggggccc ccccagggc ttaccacca gcgtgcgcag	420
ctacctgccc aacacggtga ccgacgcaact gcgggggagc gggggcgtggg ggctgctgct	480
gcgcgcgctg ggcgacgacg tgctggttca cctgctggca cgctgcgcgc tctttgtgct	540
ggtggctccc agctgcgcct accaggtgtg cgggccgccc ctgtaccagc tcggcgctgc	600
cactcaggcc cggccccgc cacacgctag tggacccca aggcgtctgg gatgcgaacg	660
ggcctggaac catagcgtca gggaggccgg ggtccccctg ggcttgccag ccccggtgc	720
gaggaggcgc gggggcagtg ccagccgaag tctgccgttg cccaagaggc ccaggcgtgg	780
cgctgcccc tggccggagc ggacggccgt tgggcagggg tcctggggcc acccgggcag	840
gacgcgtgga ccgagtgacc gtggtttctg tgtggtgtca cctgccagac ccgccgaaga	900
agccacctct ttggagggtg cgctctctgg cagcgccac tcccacccat ccgtggggccg	960
ccagcaccac gcggggcccc catccacatc gcggccacca cgtccctggg acacgccttg	1020
tccccggtg tacgcccaga ccaagcactt cctctactcc tcaggcgaca aggagcagct	1080
gcggccctcc ttcctactca gctctctgag gccagcctg actggcgctc ggaggctcgt	1140
ggagaccatc tttctgggtt ccaggccctg gatgccaggg actccccgca ggttgccccg	1200
cctgccccag cgctactggc aaatgcggcc cctgtttctg gagctgcttg ggaaccacgc	1260
gcagtgcccc tacggggtgc tcctcaagac gactgcccc ctgcgagctg cggtcacccc	1320
agcagccggt gtctgtgccc gggagaagcc ccagggtctt gtggcggccc ccgaggagga	1380
ggacacagac ccccgctgcc tggtgacgct gctccgccag cacagcagcc cctggcaggt	1440
gtacggcttc gtgcgggcct gcctgcgccg gctggtgccc ccaggcctct ggggctccag	1500
gcacaacgaa gcggcgttcc tcaggaacac caagaagttc atctccctgg ggaagcatgc	1560
caagctctcg ctgcaggagc tgacgtggaa gatgagcgtg cgggactgcg cttggctgcg	1620
caggagccca ggggttggtt gtgttccggc cgcagagcac cgtctgcgtg aggagatcct	1680
ggccaagtcc ctgcactggc tgatgagtgt gtacgtcgtc gagctgctca ggtctttctt	1740
ttatgtcacg gagaccacgt ttcaaaagaa caggctcttt ttctaccgga agagtgtctg	1800
gagcaagttg caaagcattg gaatcagaca gcaattgaag aggggtgcagc tgcgggagct	1860
gtcgggaagca gaggtcaggc agcatcggga agccaggccc gccctgctga cgtccagact	1920
ccgcttcac cccaagcctg acgggctgcg gccgattgtg aacatggact acgtcgtggg	1980
agccagaacg ttccgcagag aaaagagggc cgagcgtctc acctcgaggg tgaaggcact	2040
gttcagcgtg ctcaactacg agcgggcgcg gcgccccggc ctccctgggcg cctctgtgct	2100
gggcctggac gatatccaca gggcctggcg caccctcgtg ctgcgtgtgc gggcccagga	2160
cccgcgcct gagctgtact ttgtcaaggt ggatgtgacg ggcgcgtacg acaccatccc	2220
ccaggacagg ctacaggagg tcatcgccag catcatcaaa ccccagaaca cgtactgcgt	2280
gcgtcggtat gccgtggtcc agaaggccgc ccatgggcac gtccgcaagg cttcaagag	2340
ccacgtctct accttgacag acctccagcc gtacatgcga cagttcgtgg ctacactgca	2400
ggagaccagc ccgctgaggg atgcctcgt catcgaagc agctcctccc tgaatgaggc	2460

```

-- - - - - - - - - - - - - - - - - - - - -
cagcagtggc ctcttcgacg tcttcctacg cttcatgtgc caccacgccg tgcgcattcag 2520
gggcaagtcc tacgtccagt gccaggggat cccgcagggc tccatcctct ccacgctgct 2580
ctgcagcctg tgctacggcg acatggagaa caagctgttt gcggggattc ggcgggacgg 2640
gctgctcctg cgtttggtgg atgatttctt gttggtgaca cctcacctca cccacgcgaa 2700
aaccttcctc aggaccctgg tccgaggtgt ccctgagtat ggctgcgtgg tgaacttgcg 2760
gaagacagtg gtgaacttcc ctgtagaaga cgaggccctg ggtggcacgg cttttgttca 2820
gatgccggcc caccggcctat tcccctggtg cggcctgctg ctggataccc ggaccctgga 2880
ggtgcagagc gactactcca gctatgcccg gacctccatc agagccagtc tcaccttcaa 2940
ccgcggttcc aaggctggga ggaacatgcg tcgcaaactc tttggggctt tgcggctgaa 3000
gtgtcacagc ctgtttctgg atttgcaggt gaacagcctc cagacggtgt gcaccaacat 3060
ctacaagatc ctctgctgac aggcgtacag gtttcacgca tgtgtgctgc agctccatt 3120
tcacagcaa gtttggaaga accccacatt tttcctgcgc gtcattctctg acacggcctc 3180
cctctgtac tccatcctga aagccaagaa cgcagggatg tcgctggggg ccaagggcgc 3240
cgccggccct ctgccctccg aggcctgca gtggctgtgc caccaagcat tcctgctcaa 3300
gctgactcga caccgtgtca cctacgtgcc actcctgggg tcactcagga cagcccagac 3360
gcagctgagt cggaagctcc cggggacgac gctgactgcc ctggaggccg cagccaaccc 3420
ggcactgccc tcagacttca agaccatcct ggactgatgg ccaccgcccc acagccaggc 3480
cgagagcaga caccagcagc cctgtcacgc cgggctctac gtcccaggga gggaggggcg 3540
gcccacaccc agggccgcac cgctgggagt ctgaggcctg agtgagtgtt tggccgaggc 3600
ctgcatgtcc ggctgaaggc tgagtgtccg gctgaggcct gagcgagtgt ccagccaagg 3660
gctgagtgtc cagcacacct gccgtcttca cttccccaca ggctggcgct cggctccacc 3720
ccagggccag cttttcttca ccaggagccc ggcttccact cccacatag gaatagtcca 3780
tcccagatt cgccattgtt caccctcgc cctgccctcc tttgccttc accccacca 3840
tccaggtgga gaccctgaga aggaccctgg gagctctggg aatttggagt gaccaaaggt 3900

gtgccctgta cacaggcgag gaccctgcac ctggatgggg gtccctgtgg gtcaaattgg 3960
ggggaggtgc tgtgggagta aaatactgaa tatatgagtt tttcagtttt gaaaaaaa 4018

```

<212> Type : DNA

<211> Length : 4018

SequenceName : SEQ ID NO:8

SequenceDescription :

Sequence

<213> organismName : Foot-and-mouth disease virus

<400> PreSequenceString :

```

ggttccggaa aaattgtcgc tcctgtcaaa caaactctta actttgattt actcaaactg 60
gctggggatg tagaaagcaa tccaggtcca 90

```

<212> Type : DNA

<211> Length : 90

SequenceName : SEQ ID NO:9

SequenceDescription :

Sequence

<213> OrganismName : Cytomegalovirus

<400> PreSequenceString :

tagttattaa tagtaatcaa ttacggggtc attagttcat agcccatata tggagttccg	60
cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc cccgcccatt	120
gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc attgacgtca	180
atgggtggag tatttacggt aaactgccca cttggcagta catcaagtgt atcatatgcc	240
aagtacgcc cctattgacg tcaatgacgg taaatggccc gcctggcatt atgccagta	300
catgacctta tgggactttc ctacttgga gtacatctac gtattagtca tcgctattac	360
catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg actcacgggg	420
atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc aaaatcaacg	480
ggactttcca aaatgtcgta acaactccgc ccattgacg caaatgggcg gtaggcgtgt	540
acgggtggag gtctatataa gcagagctgg tttagtgaac cgtcagatc	589

<212> Type : DNA

<211> Length : 589

SequenceName : SEQ ID NO:10

SequenceDescription :

Sequence

<213> OrganismName : Homo sapiens

<400> PreSequenceString :

ctagcttcgt gaggtccgg tggccgtcag tgggcagagc gcacatcgcc cacagtcccc	60
gagaagtgg ggggaggggt cggcaattga accggtgcct agagaagggtg gcgcggggta	120
aactgggaaa gtgatgtcgt gtactggctc cgcctttttc ccgaggggtgg gggagaaccg	180
tatataagtg cagtagtcgc cgtgaacgtt ctttttcgca acgggtttgc cgccagaaca	240
caggtaagtg ccgtgtgtgg ttcccgggg cctggcctct ttacgggtta tggcccttgc	300
gtgccttgaa ttacttcac ctggctccag tacgtgattc ttgatcccg gctggagcca	360
ggggcgggcc ttgcgcttta ggagcccctt cgcctcgtgc ttgagttgag gcctggcctg	420
ggcgtgggg ccgcccgtg cgaatctggt ggcaccttcg cgcctgtctc gctgctttcg	480
ataagtctct agccatttaa aatttttgat gacctgtgc gacgcttttt ttctggcaag	540
atagtcttgt aaatgcgggc caggatctgc aactggtat ttcggttttt gggcccgcgg	600
ccggcgacgg ggcccgtgcg tcccagcgca catgttcggc gaggcggggc ctgcgagcgc	660
ggccaccgag aatcgacgg ggtagtctc aagctggccg gcctgctctg gtgcctggcc	720
tcgcgccgcc gtgtatcgcc ccgccctggg cggcaaggct ggcccggctg gcaccagttg	780
cgtgagcggg aagatggccg ctcccggcc ctgctccagg gggctcaaaa tggaggacgc	840
ggcgtcggg agagcggg ggtgagtcac ccacaaaag gaaaaggggc tttccgtcct	900
cagccgtcgc ttcatgtgac tccacggagt accgggcgcc gtccaggcac ctcgattagt	960
tctggagctt ttggagtacg tcgtctttag gttgggggga ggggttttat gcgatggagt	1020
ttccccacac tgagtgggtg gagactgaag ttaggccagc ttggcacttg atgtaattct	1080

```

cgttggaatt tgcccttttt gagtttggat cttggttcat tctcaagcct cagacagtgg 1140
ttcaaagttt ttttcttcca tttcaggtgt cgtgaacacg tggtcgcggc ca 1192

```

<212> Type : DNA

<211> Length : 1192

SequenceName : SEQ ID NO:11

SequenceDescription :

sequence

<213> OrganismName : Homo sapiens

<400> PreSequenceString :

```

ctagcttcgt gaggtccgg tggcgtcag tgggcagagc gcacatcgcc cacagtcccc 60
gagaagtgg ggggaggggt cggcaattga accggtgcct agagaagggt gcgcggggta 120
aactgggaaa gtgatgtcgt gtactggctc cgcctttttc ccgaggggtgg gggagaaccg 180
tatataagtg cagtagtcgc cgtgaacgtt ctttttcgca acgggtttgc cgccagaaca 240
caggtaagtg ccgtgtgtgg ttcccgcggg cctggcctct ttacgggtta tggcccttgc 300
gtgccttgaa ttacttcac ctggctccag tacgtgattc ttgatcccga gctggagcca 360
ggggcgggcc ttgcgcttta ggagcccctt cgcctcgtgc ttgagttgag gcctggcctg 420
ggcgtgggg ccgcccgtg cgaatctggt ggcaccttcg cgcctgtctc gctgctttcg 480
ataagtctct agccatttaa aatttttgat gacctgtgc gacgcttttt ttctggcaag 540
atagtcttgt aaatgcgggc caggatctgc aactggtat ttcggttttt gggcccgcgg 600
ccggcgacgg ggcccgtgcg tcccagcgca catgttcggc gaggcggggc ctgcgagcgc 660

ggccaccgag aatcggacgg gggtagtctc aagctggccg gcctgctctg gtgcctggcc 720
tcgcgccgcc gtgtatcgcc ccgccctggg cggcaaggct ggcccggtcg gcaccagtgt 780
cgtgagcggg aagatggcgg cttcccggcc ctgctccagg gggctcaaaa tggaggacgc 840
ggcgtcggg agagcgggcg ggtgagtcac ccacacaaag gaaaagggcc tttccgtcct 900
cagccgtcgc ttcattgtgac tccacggagt accgggcgcc gtccaggcac ctcgattagt 960
tctggagctt ttggagtacg tcgtcttttag gttgggggga ggggttttat gcgatggagt 1020
ttccccacac tgagtgggtg gagactgaag ttaggccagc ttggcacttg atgtaattct 1080
cgttggaatt tgcccttttt gagtttggat cttggttcat tctcaagcct cagacagtgg 1140
ttcaaagttt ttttcttcca tttcaggtgt cgtgaacacg tggtcgcggc ca 1192

```

<212> Type : DNA

<211> Length : 1192

SequenceName : SEQ ID NO:12

SequenceDescription :

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US20060128018A [0028]

Non-patent literature cited in the description

- THOMSON et al.Science, 1998, vol. 282, 1145-1147 [0001]
- BYRNE, JA et al.Nature, 2007, vol. 450, 497-502 [0002]
- YU, J et al.Stem Cells, 2006, vol. 24, 168-176 [0002]
- YU et al.Science, 2007, vol. 318, 1917-1920 [0002]
- TAKAHASHI et al.Cell, 2007, vol. 131, 861-872 [0002]
- LOWRY et al.PNAS, 2008, vol. 105, 2883-2888 [0003]
- DIMOS et al.Science, 2008, vol. 321, 1218-1221 [0003]
- OKITA et al.Nature, 2007, vol. 448, 313-317 [0004]
- ASKEW et al.Oncogene, 1991, vol. 6, 1915-1922 [0005]
- EVAN et al.Cell, 1992, vol. 69, 119-128 [0005]
- STADTFELD et al.Scienceexpress, 2008, [0006]
- LINDNER, S.E.B. SUGDENThe plasmid replicon of Epstein-Barr virus: mechanistic insights into efficient, licensed, extrachromosomal replication in human cellsPlasmid, 2007, vol. 58, 1- [0018]
- SAMBROOK J et al.Molecular cloning: a laboratory manualCold Spring harbor Press20010000 [0018]
- ZWAKATHOMSONNature Biotechnology, 2003, vol. 21, 319-321 [0028]
- HERMEKING et al.PNAS, 1994, vol. 91, 10412-10416 [0031]
- HANNA et al.Cell, 2008, vol. 133, 250-264 [0031]
- MALI et al.Stem Cells, 2008, [0031]
- AMIT et al.Developmental Biology, 2006, vol. 227, 271-278 [0034]
- LUDWIG et al.Nature Methods, 2006, vol. 3, 637-646 [0034]
- XU et al.Nat. Biotechnol., 2001, vol. 19, 971- [0039]

PATENTKRAV

1. Fremgangsmåde *in vitro* til omprogrammering somatiske primatceller, hvilken fremgangsmåde omfatter trinnene med:

eksponering af de somatiske primatceller for mindst én ikke-viral episomal vektor, 5 der koder for en flerhed af potensbestemmende faktorer, og indføring af SV40 T-antigen i de somatiske primatceller under forhold, der er tilstrækkelige til omprogrammering af cellerne, hvor de somatisk primatceller opnås fra et føtalt eller post-natalt individ; og

dyrkning af de eksponerede celler for at opnå pluripotente omprogrammerede celler 10 i alt væsentligt fri for nogen ikke-viral episomal vektorkomponent forbundet med eksponering af de potensbestemmende faktorer for de somatiske celler.

2. Fremgangsmåde ifølge krav 1, hvor

(a) primaten er et menneske; eller

(b) de omprogrammerede celler i alt væsentligt er genetisk identiske med det 15 føtale eller post-natale individ.

3. Fremgangsmåde ifølge krav 1, hvor flerheden af potensbestemmende faktorer er valgt fra gruppen bestående af human OCT-4, human SOX2, human LIN28, human NANOG, human c-Myc og human KLF4.

4. Fremgangsmåde ifølge krav 1, hvor den mindst ene vektor er en enkelt 20 vektor.

5. Fremgangsmåde ifølge krav 4, hvor den enkelte vektor omfatter

(a) mindst ét internt ribosomalt indgangssted;

(b) i rækkefølge, en første promotor, *OCT4*, *IRES2*, *SOX2*, en anden promotor, *SV40 T*-antigen, *IRES2* og *KLF4*; eller

(c) i rækkefølge, en første promotor, *OCT4*, *IRES2*, *SOX2*, en anden 25 promotor, *c-Myc*, *IRES 2*, *KLF4*, en tredje promotor, *NANOG*, *IRES2* og *LN28*.

6. Fremgangsmåde ifølge krav 1, hvor en første vektor omfatter, i rækkefølge, en første promotor, *OCT4*, *IRES2*, *SOX2*, en anden promotor, *SV40 T*-antigen, *IRES2* og *KLF4*, hvor en anden vektor omfatter, i rækkefølge, en tredje promotor,

OCT4, IRES2, *SOX2*, en fjerde promotor, *NANOG*, IRES2 og *KLF4*, og hvor en tredje vektor omfatter, i rækkefølge, en femte promotor, *c-Myc*, IRES 2 og *LN28*, hvor promotorerne ikke skal være identiske.

5 7. Fremgangsmåde ifølge krav 6, hvor hver af den første, anden, tredje og fjerde promotor er en elongeringsfaktor 1 α - (EF1 α) genpromotor.

8. Fremgangsmåde ifølge krav 1, hvor en første vektor omfatter, i rækkefølge, en første promotor, *OCT4*, IRES2, *SOX2*, en anden promotor, *KLF4*, IRES2, *c-Myc*, en tredje promotor, *NANOG*, IRES2, og *LN28*, hvor en anden vektor omfatter, i rækkefølge, en fjerde promotor, *OCT4*, IRES2, *SOX2*, en femte promotor, *SV40 T*-
10 antigen, IRES2 og *KLF4*, hvor promotorerne ikke skal være identiske.

9. Fremgangsmåde ifølge krav 8, hvor hver af den første, tredje, fjerde og femte promotor er en EF1 α -genpromotor og hvor den anden promotor er en umiddelbar tidlig cytomegalovirus- (CMV) genpromotor.

10. Fremgangsmåde ifølge krav 1, hvor en første vektor omfatter, i
15 rækkefølge, en første promotor, *OCT4*, IRES2, *SOX2*, en anden promotor, *NANOG*, IRES2 og *LN28*, hvor en anden vektor omfatter, i rækkefølge, en tredje promotor, *OCT4*, IRES2, *SOX2*, en fjerde promotor, *SV40 T*-antigen, IRES2 og *KLF4*, og hvor en tredje vektor omfatter, i rækkefølge, en femte promotor, *OCT4*, IRES2, *SOX2*, en sjette promotor, *c-Myc*, IRES 2 og *KLF4*, hvor promotorerne ikke skal være
20 identiske.

DRAWINGS

Fig. 1A




Fig. 1B




FIGURE 1

Fig. 2A




Fig. 2B




Fig. 2C




FIGURE 2

Fig. 3A




Fig. 3B




Fig. 3C




FIGURE 3




Fig. 4B




Fig. 4C




Fig. 4D




FIGURE 4




Fig. 5A




Fig. 5B

FIGURE 5